Hims & Hers Health (NYSE:HIMS) Price Target Raised to $27.00 at Truist Financial

Hims & Hers Health (NYSE:HIMS) had its price objective increased by Truist Financial from $23.00 to $27.00 in a report released on Friday,Benzinga reports. They currently have a hold rating on the stock.

A number of other equities analysts also recently issued reports on HIMS. TD Cowen dropped their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Bank of America upped their price target on Hims & Hers Health from $36.00 to $37.00 and gave the stock a “neutral” rating in a research report on Thursday, July 9th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a report on Friday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $31.43.

Hims & Hers Health Stock Performance

HIMS stock opened at $28.10 on Friday. The stock has a market capitalization of $6.50 billion, a PE ratio of -312.26, a price-to-earnings-growth ratio of 92.14 and a beta of 2.35. The stock’s 50 day simple moving average is $30.75 and its 200 day simple moving average is $26.34. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, research analysts forecast that Hims & Hers Health will post 0.03 earnings per share for the current fiscal year.

Insider Activity

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells acquired 48,400 shares of Hims & Hers Health stock in a transaction on Tuesday, May 26th. The shares were purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director directly owned 224,417 shares in the company, valued at $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have sold 83,126 shares of company stock valued at $2,711,339. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC boosted its stake in shares of Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after purchasing an additional 75,679 shares in the last quarter. Vanguard Group Inc. raised its stake in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new position in Hims & Hers Health in the fourth quarter worth approximately $11,187,000. Cunning Capital Partners LP purchased a new stake in Hims & Hers Health during the fourth quarter worth $1,110,000. Finally, Virtu Financial LLC bought a new stake in Hims & Hers Health during the 4th quarter valued at $1,937,000. Institutional investors own 63.52% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The FDA panel’s favorable peptide recommendation could eventually broaden Hims & Hers’ addressable market and support its emerging peptide therapy business. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Neutral Sentiment: Truist raised its price target on HIMS to $27 from $23, but kept a hold rating, suggesting the firm sees limited upside from current levels. Tickerreport.com
• Neutral Sentiment: Recent commentary and search interest have kept HIMS in focus, reflecting elevated trading attention around the FDA-driven peptide story. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: The sharp pullback appears consistent with a sell-the-news move as traders locked in gains after the initial FDA-related spike, since the regulatory process is not finished. Why Is HIMS Stock Rallying 13% Today?
• Negative Sentiment: Insider selling and mixed hedge fund positioning may also weigh on investor sentiment, as many major holders reduced exposure in the latest quarter. Hims & Hers Health Slides as Traders Fade Peptide Rally

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.